Biotech Investment Analyst — Drug Asset & Company Assessment

Mercor (client confidential) · Remote — US-based or deep US-market experience · Remote

Pay
$120–200/hr
Commitment
part-time
Hours / week
~15
Source
mercor
Apply on mercorGoes straight to the source — we never paywall the apply link.

Is this job right for you?

Get job recommendations matched to your experience, first access to exclusive opportunities, and no ads.

Get jobs matched to your experience

About this role

Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales. **Responsibilities** - Create and critique rubrics that analyze commercial drugs and drug-development programs - Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers - Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions - Apply your assessment across the pilot's set of companies (~5–10) **Requirements** - US-based biotech / healthcare investment analyst with a specialist-fund background - Familiarity with biotech/pharma development programs - Able to assess a drug asset and the company behind it end-to-end - 5+ years evaluating biotech/pharma companies or assets **Engagement Details** - Duration: Approximately 10–20 hours over a 1–2 week pilot - Remote — US-based **Why Participate** - Help improve expert AI evaluation of drugs and drug-development programs - Recurring engagement for strong contributors

Skills & domains